Literature DB >> 10851445

Patterns of hepatic and splenic colonization by an attenuated strain of Salmonella typhimurium containing the gene for human interleukin-2: a novel anti-tumor agent.

D A Saltzman1, E Katsanis, C P Heise, D E Hasz, S M Kelly, R Curtiss, A S Leonard, P M Anderson.   

Abstract

Currently, there is no effective treatment for unresectable hepatic malignancies. Salmonella sp. are known to naturally track to the liver during active infection. A live biological vector was developed for delivery of Interleukin-2 (IL-2) to the liver for anti-tumor purposes. The avirulent and highly immunogenic c4550 strain of Salmonella typhimurium was used to express the IL-2 protein [renamed c4550(pIL-2)]. We have previously demonstrated that the c4550(pIL-2) produces biologically active IL-2 (up to 46.2 IU/ml) and that a single gavage feeding of 10(7) colony forming units (cfu) of c4550(pIL-2) significantly reduced the number of hepatic metastases when compared to animals fed salmonella lacking the IL-2 gene or non-treated controls. The goal of the current studies was to determine the pattern of splenic and hepatic colonization of Salmonella-IL2. Hepatic and splenic colonization was determined following administration of 10(7) cfu of c4550(pIL-2) and c4550(pYA292) via a single gavage feeding to C57BL/6 mice. Five experiments of antibiotic regimen administration were conducted where splenic and hepatic homogenates were cultured after 14 days of parenteral and/or oral antibiotics. The natural history of hepatic and splenic colonization was also determined for animals without antibiotic treatment. Despite administration of various antibiotic regimens using different routes, eradication of salmonella with and without IL-2 was not achieved. Salmonella, however, was not cultured from hepatic and splenic tissue at 4 months after a single gavage feeding of salmonella with no specific treatment. In conclusion, oral administration of c4550(pIL-2) may represent a novel form of in vivo biotherapy for unresectable hepatic malignancies. Antibiotics do not accelerate eradication of this bacteria and it appears that c4550(pIL-2) follows the natural pathophysiological of salmonella infection in which eradication from the splenic and hepatic tissue occurs over a period of 2-4 months.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10851445     DOI: 10.1089/cbr.1997.12.37

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  5 in total

1.  Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model.

Authors:  Brent Sorenson; Kaysie Banton; Lance Augustin; Sean Barnett; Karen McCulloch; Joshua Dorn; Natalie Frykman; Arnold Leonard; Daniel Saltzman
Journal:  Biologics       Date:  2010-03-24

Review 2.  Bacteria in cancer therapy: a novel experimental strategy.

Authors:  S Patyar; R Joshi; D S Prasad Byrav; A Prakash; B Medhi; B K Das
Journal:  J Biomed Sci       Date:  2010-03-23       Impact factor: 8.410

3.  Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma.

Authors:  Brent S Sorenson; Kaysie L Banton; Natalie L Frykman; Arnold S Leonard; Daniel A Saltzman
Journal:  Clin Orthop Relat Res       Date:  2008-04-18       Impact factor: 4.176

4.  A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma.

Authors:  Sara E Fritz; Michael S Henson; Emily Greengard; Amber L Winter; Kathleen M Stuebner; Una Yoon; Vicki L Wilk; Antonella Borgatti; Lance B Augustin; Jaime F Modiano; Daniel A Saltzman
Journal:  Vet Med Sci       Date:  2016-06-06

5.  Collagenase-Expressing Salmonella Targets Major Collagens in Pancreatic Cancer Leading to Reductions in Immunosuppressive Subsets and Tumor Growth.

Authors:  Nancy D Ebelt; Vic Zamloot; Edith Zuniga; Kevin B Passi; Lukas J Sobocinski; Cari A Young; Bruce R Blazar; Edwin R Manuel
Journal:  Cancers (Basel)       Date:  2021-07-16       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.